{"gene":"CD38","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1996,"finding":"CD38 functions as a bifunctional ectoenzyme that catalyzes both the synthesis and hydrolysis of cyclic ADP-ribose (cADPR), a Ca2+-mobilizing second messenger acting independently of inositol trisphosphate. It also functions as a receptor capable of mediating transmembrane signals and can be internalized in response to appropriate stimuli.","method":"Biochemical ectoenzyme assays, internalization experiments, functional antibody ligation studies in hematopoietic cells","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — enzymatic activity reconstituted biochemically, replicated across multiple labs and cell types, foundational mechanistic characterization","pmids":["8903511"],"is_preprint":false},{"year":1997,"finding":"The topological paradox of CD38's ectocellular catalytic domain synthesizing the intracellular messenger cADPR may be resolved by two mechanisms: (a) influx of extracellular cADPR across the plasma membrane to reach ryanodine-sensitive intracellular stores, and (b) NAD+-induced internalization of CD38 following membrane oligomerization, importing cADPR metabolism to an intracellular compartment, as observed in lymphoid B cells.","method":"Biochemical fractionation, NAD+-induced internalization experiments in lymphoid B cells, cerebellar granule cell Ca2+ signaling studies","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct internalization experiments in B cells, single lab, two proposed mechanisms with partial experimental support","pmids":["9438379"],"is_preprint":false},{"year":1994,"finding":"CD38 ligation on murine B cells stimulates protein tyrosine kinase activity but does not mobilize intracellular calcium stores and is not coupled to generation of inositol phosphates, indicating CD38 signals through a distinct pathway from classical PLC-coupled receptors.","method":"Calcium flux assays, inositol phosphate measurements, protein tyrosine phosphorylation assays in murine B cells using mitogenic anti-CD38 antibody NIMR-5","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical assays in single lab, clear mechanistic distinction established","pmids":["7875731"],"is_preprint":false},{"year":2001,"finding":"CD38 ligation on human NK cells activates a signaling cascade including intracellular Ca2+ elevation, tyrosine phosphorylation of CD3-zeta, FcεRIγ, ZAP-70, and c-Cbl, and induces IFN-γ and GM-CSF secretion and cytolytic function. These CD38-mediated signals were absent in CD16-negative NK cell lines, establishing that CD38 requires CD16 (FcγRIIIA) as a co-signaling partner in NK cells.","method":"Calcium flux assays, tyrosine phosphorylation assays, cytokine secretion assays, cytotoxicity assays, genetic complementation of CD16-negative NK lines with CD16 expression","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays, genetic complementation approach, single lab","pmids":["11282979"],"is_preprint":false},{"year":2002,"finding":"CD38 physically associates with CD16 on the surface of human NK cells, as demonstrated by FRET and cocapping experiments. Functional CD16 is necessary and sufficient for CD38 to control an activation pathway including calcium fluxes, ZAP-70 and MAPK phosphorylation, IFN-γ secretion, and cytotoxic responses, establishing CD38 as a receptor that signals through lineage-specific co-association with professional signaling molecules.","method":"FRET, cocapping, calcium flux, tyrosine phosphorylation, IFN-γ secretion, cytotoxicity assays in CD16+ and CD16- NK variants","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — FRET-based physical association plus multiple functional assays, reciprocal genetic approach with CD16+/- NK variants","pmids":["11895784"],"is_preprint":false},{"year":2008,"finding":"During immunological synapse (IS) formation, CD38 redistributes to the T cell–APC contact area in an antigen-dependent manner via Lck-mediated signals. Two distinct pools of CD38 exist—one at the plasma membrane and one in recycling endosomes—and both are recruited to the IS. CD38 overexpression increases antigen-induced intracellular Ca2+ release; siRNA knockdown reduces it. CD38 blockade inhibits IL-2 and IFN-γ production, PKCθ phosphorylation (Thr538), and PKCθ recruitment to the IS.","method":"Confocal microscopy, CD38-GFP live imaging, siRNA knockdown, Ca2+ flux assays, cytokine ELISA, PKCθ phosphorylation assays in human T cells and B cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (imaging, genetic KD, Ca2+ flux, signaling assays), two cell types, single lab with rigorous controls","pmids":["18212246"],"is_preprint":false},{"year":2012,"finding":"CD38 exists in two opposing membrane orientations on cell surfaces: the canonical type II orientation (catalytic C-terminal domain extracellular) and a type III orientation (catalytic domain facing intracellularly). Site-directed mutagenesis of cationic residues in the N-terminal segment converts the mixed type II/III distribution to exclusively type III. Expression of type III CD38 increases intracellular cADPR concentrations, establishing the type III orientation as critical for intracellular Ca2+ signaling.","method":"Orientation-specific antibodies against N-terminal segment, site-directed mutagenesis, intracellular cADPR measurement in transfected HL-60 cells, monocytes, and U937 cells stimulated with IFN-γ","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with orientation-specific antibodies and functional cADPR measurement, orthogonal methods in multiple cell types","pmids":["22969159"],"is_preprint":false},{"year":2011,"finding":"CD38 activity generates the second messengers NAADP and cADPR. Gene silencing of CD38 did not inhibit NAADP synthesis in intact Jurkat T cells or in thymus/spleen from CD38 knockout mice, but in vitro CD38 efficiently catalyzed both NAADP formation (by base-exchange) and NAADP degradation. This establishes that in vivo CD38 functions as a NAADP-degrading rather than NAADP-synthesizing enzyme, likely preventing desensitizing NAADP levels.","method":"CD38 gene silencing (siRNA), CD38 knockout mouse tissues, in vitro enzymatic assays for NAADP formation and degradation","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic assay plus genetic KO/KD in intact cells, single lab, clear mechanistic conclusion","pmids":["22020217"],"is_preprint":false},{"year":2018,"finding":"CD38 produces NAADP in the endolysosomal compartment. Nanobody-induced endocytosis of CD38 via a clathrin-dependent pathway delivers CD38 to lysosomes and elevates cellular NAADP levels. A lysosome-targeted CD38 variant is substantially more active in raising NAADP levels than wild-type CD38, and nicotinic acid supplementation further increases NAADP production, demonstrating that CD38 compartmentalization and substrate access—rather than enzyme activation—regulate NAADP production.","method":"Nanobody-directed endocytosis, lysosome-specific CD38 targeting constructs, intracellular NAADP measurement, clathrin inhibitor studies in human cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstitution of lysosomal NAADP production with targeted constructs, multiple orthogonal approaches, substrate access mechanism demonstrated","pmids":["29632067"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of CD38 complexed with anti-CD38 nanobodies identified three separate epitopes on the carboxyl (catalytic) domain of CD38. Chromobody (nanobody-fluorescent protein fusions) tools confirmed high CD38 expression on malignant MM cells. An immunotoxin (nanobody fused to bacterial toxin PE38) showed selective cytotoxicity against MM cells at picomolar concentrations.","method":"X-ray crystallography of CD38–nanobody complexes, flow cytometry quantification with chromobodies, in vitro cytotoxicity assays with immunotoxin","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures resolve epitopes with functional validation by immunotoxin cytotoxicity, single lab with rigorous structural methods","pmids":["27251573"],"is_preprint":false},{"year":2001,"finding":"CD38 functions as a receptor that interacts with CD31 (PECAM-1) on the surface of leukocytes, mediating adhesion and signaling. The CD38–CD31 interaction constitutes a ligand–receptor pair governing leukocyte adhesion and transmembrane signaling.","method":"Receptor-ligand binding studies, adhesion assays, signaling assays in leukocytes","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct binding interaction identified with functional adhesion readout, replicated across reports cited in review","pmids":["11137554"],"is_preprint":false},{"year":2008,"finding":"CD38 expression on CLL cells is upregulated by contact with activated CD4+ T cells, is higher in pseudofollicle-containing tissues, and marks proliferating CLL cells associated with CD31+ vascular endothelial cells. This establishes CD38 expression as dynamically regulated by the tumor microenvironment through T cell contact.","method":"Flow cytometry, tissue immunohistochemistry, in vitro co-culture of CLL cells with activated CD4+ T cells, comparison of tissue vs. blood CD38 levels","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct co-culture experiment demonstrating T cell-driven CD38 upregulation, supported by tissue analysis, single lab","pmids":["18326821"],"is_preprint":false},{"year":2012,"finding":"LPS induces CD38 upregulation at the mRNA level in J774 macrophages via the JAK-STAT pathway and simultaneously causes CD38 shedding from the plasma membrane into the extracellular space via metalloproteinase-9 (MMP-9), as demonstrated by MMP-9 inhibitor blockade of CD38 release.","method":"Flow cytometry, RT-PCR, JAK-STAT pathway inhibitors, metalloproteinase-9 inhibitor, ELISA for soluble CD38 in culture supernatant","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway identified with specific inhibitors, single lab, multiple methods","pmids":["23184288"],"is_preprint":false},{"year":2011,"finding":"PI3K p110δ regulates CD38 expression on regulatory T cells (Tregs): p110δ-inactivated Tregs fail to develop CD38high cells. CD38high Tregs display superior suppressive activity and upregulate CD73 compared to CD38low Tregs. CD38 marks Tregs with high suppressive capacity downstream of PI3K p110δ signaling.","method":"Transcriptome comparison of wild-type vs. p110δ(D910A) Tregs, flow cytometry, Treg suppression assays, CD38+/- heterozygous mouse analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with defined Treg phenotype, multiple cell comparisons, single lab","pmids":["21390257"],"is_preprint":false},{"year":2017,"finding":"CD38 promotes angiotensin II-induced cardiac hypertrophy by inhibiting SIRT3 expression and activating Ca2+-NFAT signaling. CD38 knockout mice show significantly reduced cardiac hypertrophy and fibrosis after Ang-II infusion compared to wild-type. In H9c2 cardiomyocytes, CD38 RNAi knockdown decreases ANF and BNP gene expression, reduces ROS generation, elevates SIRT3, activates FOXO3 antioxidant pathway, and markedly reduces Ang-II-induced intracellular Ca2+ release and NFATc4 nuclear translocation.","method":"CD38 knockout mice with osmotic mini-pump Ang-II infusion, cardiac histology, RNAi knockdown in H9c2 cells, intracellular Ca2+ measurement, Western blotting for SIRT3/FOXO3/NFATc4/ERK/AKT","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO plus in vitro KD with multiple signaling pathway readouts, single lab","pmids":["28296029"],"is_preprint":false},{"year":2020,"finding":"During sepsis resolution, CD38 levels increase to produce Ca2+-signaling messengers (NAADP, ADPR, cADPR) from NAD(P)+. These second messengers induce tristetraprolin (TTP) expression, which then downregulates CD38. Sirt1-dependent TTP deacetylation (activated by increased NAD+ levels) suppresses acute inflammation, decreases Rheb, inhibits mTORC1, and induces autophagolysosomes for bacterial clearance, defining a CD38–TTP feedback loop in inflammation resolution.","method":"Sepsis mouse models, CD38 and TTP KO mice, Sirt1 inhibition, mTORC1 signaling assays, autophagolysosome formation assays, second messenger measurements","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO models plus signaling pathway dissection, single lab, multiple orthogonal methods","pmids":["31995750"],"is_preprint":false},{"year":2018,"finding":"CD38 enzymatic activity (NADase) depletes intracellular NAD+ in prostate cancer cells, causing cell-cycle arrest with p21Cip1 upregulation, diminishing glycolytic and mitochondrial metabolism, activating AMPK, and inhibiting fatty acid/lipid synthesis. Expression of an NAD+ hydrolase-deficient CD38 mutant failed to reproduce these metabolic effects, establishing NADase activity as the mechanistic basis.","method":"CD38 overexpression and NADase-deficient mutant in prostate cancer cell lines, NAD+ measurement, cell-cycle analysis, metabolic flux assays (Seahorse), AMPK phosphorylation, transcriptome profiling","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — catalytic mutant controls establish enzymatic mechanism, multiple orthogonal metabolic readouts, single rigorous study","pmids":["30076241"],"is_preprint":false},{"year":2018,"finding":"CD38 overexpression in prostate epithelial cells depletes extracellular (but not intracellular) NAD+ levels, as confirmed by wild-type vs. NAD+ hydrolase-deficient mutant comparisons in cell lines and by NAD+ measurements in urogenital tissues from CD38 knockout vs. wild-type mice.","method":"Inducible CD38 overexpression, NADase-deficient CD38 mutant, NAD+ measurements in culture medium and tissues, CD38 KO mouse urogenital tissue analysis","journal":"Cancer & metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — catalytic mutant plus KO mouse model with direct NAD+ measurements, single lab with rigorous controls","pmids":["30258629"],"is_preprint":false},{"year":2020,"finding":"Pro-inflammatory M1-like macrophages accumulate in visceral adipose tissue and liver during aging and express high levels of CD38 with enhanced CD38-dependent NADase activity, thereby reducing tissue NAD+ levels. Senescent cell-derived SASP cytokines induce macrophages to proliferate and upregulate CD38, establishing a causal chain: senescence → SASP → macrophage CD38 induction → NAD+ decline.","method":"Flow cytometry of tissue macrophage subsets, CD38 NADase activity assays, senescent cell depletion, SASP cytokine treatment of macrophages, tissue NAD+ measurement in aged mice","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct CD38-dependent NADase activity measurements in isolated macrophages, SASP induction experiments, senescent cell depletion rescue, multiple orthogonal approaches","pmids":["33199924"],"is_preprint":false},{"year":2018,"finding":"In human macrophages and monocytes, CD38 expression is robustly induced by LPS ± IFN-γ but not by IL-4. Pharmacologic and/or genetic CD38 loss-of-function significantly reduced secretion of inflammatory cytokines IL-6 and IL-12p40 and glycolytic activity in primary human macrophages.","method":"LPS/IFN-γ/IL-4 stimulation of human primary macrophages, siRNA knockdown, pharmacological inhibition, ELISA for cytokines, glycolysis assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological KD with functional cytokine and metabolic readouts, single lab, multiple methods","pmids":["30042766"],"is_preprint":false},{"year":2018,"finding":"Daratumumab (anti-CD38 antibody) induces rapid CD38 protein internalization and degradation on NK cells, leaving an activated CD38-negative NK cell population. CD38+ NK cell targeting by daratumumab promotes monocyte activation, increasing T-cell costimulatory molecules (CD86/CD80) and enhancing anti-MM phagocytosis.","method":"Flow cytometry of NK cell CD38 expression after daratumumab treatment, monocyte activation assays, co-culture cytotoxicity/phagocytosis assays ex vivo and in vivo (mouse xenograft)","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein internalization/degradation measured by flow cytometry with functional monocyte activation readout, single lab","pmids":["32296125"],"is_preprint":false},{"year":2018,"finding":"Daratumumab treatment causes CD38 internalization on MM cell surfaces via dynamin-dependent endocytosis and impairs MM cell adhesion; this adhesion impairment can be rescued by the endocytosis inhibitor Dynasore. CD38 internalization-mediated loss of adhesion increases MM cell sensitivity to bortezomib.","method":"Flow cytometry of surface CD38 after daratumumab, Dynasore endocytosis inhibitor rescue of adhesion, in vitro and in vivo bortezomib combination studies","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endocytosis inhibitor rescue experiment mechanistically links internalization to adhesion impairment, in vitro and in vivo validation, single lab","pmids":["30288349"],"is_preprint":false},{"year":2019,"finding":"CD38 modulates B-cell receptor (BCR) signaling in CLL: interference with CD38 downregulates Syk, BTK, PLCγ2, ERK1/2, and AKT phosphorylation. Daratumumab additionally induces direct apoptosis of primary CLL cells partially dependent on FcγR cross-linking, beyond its immune-effector mechanisms.","method":"Immunoblotting of BCR signaling intermediates after CD38 targeting/blockade, apoptosis assays, FcγR blocking experiments, in vivo CLL xenograft model","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Western blotting of signaling cascade downstream of CD38, in vitro and in vivo validation, single lab","pmids":["30940652"],"is_preprint":false},{"year":2022,"finding":"CD38 elevation in alveolar epithelial cells (AECs) downregulates intracellular NAD+, impairing NAD-dependent cellular activities and promoting cellular aging phenotypes and lung fibrosis. Genetic and pharmacological inactivation of CD38 improved NAD-dependent events and ameliorated bleomycin-induced lung fibrosis in mice.","method":"scRNA-seq, Western blotting, flow cytometry, CD38 KO mice, pharmacological CD38 inhibition, bleomycin fibrosis model, NAD+ measurement","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with NAD+ measurement and fibrosis readout, single lab","pmids":["35687485"],"is_preprint":false},{"year":2023,"finding":"CD38 expression in the ovary increases with reproductive age, and CD38 knockout mice exhibit larger primordial follicle pools, elevated ovarian NAD+ levels, and increased fecundity. The larger ovarian reserve results from a prolonged window of follicle formation during early development, establishing that CD38-dependent NAD+ consumption accelerates the depletion of ovarian reserve.","method":"CD38 KO mouse reproductive phenotyping, ovarian NAD+ measurement, primordial follicle counting, fecundity assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with direct NAD+ measurement and follicle reserve quantification, single lab, clean loss-of-function","pmids":["37822499"],"is_preprint":false},{"year":2023,"finding":"Pharmacological inhibition or genetic knockout of CD38 in chondrocytes increases the intracellular NAD+:NADH ratio and reduces catabolic responses to IL-1β. In vivo, CD38-deficient mice show significantly reduced cartilage degradation, synovial inflammation, osteophyte formation, subchondral bone sclerosis, and pain-like behavior after joint injury.","method":"CD38 overexpression and pharmacological inhibition in chondrocytes, NAD+:NADH ratio measurement, catabolic gene expression, CD38 KO mice with DMM surgery, cartilage histology, pain behavior assays","journal":"Arthritis & rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with direct NAD+:NADH measurement, in vivo KO model with multiple disease readouts, single lab","pmids":["36103412"],"is_preprint":false},{"year":2022,"finding":"High CD38 expression increases cellular ROS levels and induces oxidative degradation of dihydrofolate reductase (DHFR) via sulfonation of Cys7, leading to DHFR degradation through autophagy and non-canonical proteasome pathways. This DHFR loss increases cellular susceptibility to ferroptosis. Mutation of DHFR Cys7 to alanine abolishes ROS-induced degradation, and NMN supplementation (to restore NAD+) prevents DHFR degradation and ferroptosis susceptibility.","method":"CD38 overexpression, ROS measurement, site-directed mutagenesis of DHFR Cys7, autophagy/proteasome pathway inhibitors, ferroptosis assays, aged vs. young bone-marrow-derived macrophage comparisons, NMN supplementation rescue","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis identifies specific residue, multiple pathway inhibitors, rescue by NAD+ precursor, single lab","pmids":["36351893"],"is_preprint":false},{"year":2022,"finding":"TNB-738, a biparatopic anti-CD38 antibody binding two non-competing epitopes simultaneously, potently inhibits CD38 ecto-enzyme activity, boosting intracellular NAD+ levels and sirtuin (SIRT) activities without depleting CD38-expressing cells (due to silenced IgG4 Fc).","method":"Fluorescence spectroscopy enzymatic activity assays, intracellular NAD+ measurement, sirtuin activity assays, ADCC/CDC assays confirming lack of cell depletion, SPR binding studies","journal":"mAbs","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct enzymatic inhibition assay with functional NAD+ and SIRT activity readouts, single lab, multiple orthogonal methods","pmids":["35867844"],"is_preprint":false},{"year":2023,"finding":"HexaBody-CD38 binds a unique epitope on CD38 (identified by co-crystallization) and strongly inhibits CD38 cyclase activity. The E430G Fc mutation facilitates antibody hexamerization upon cell-surface binding, increasing C1q recruitment and potentiating complement-dependent cytotoxicity (CDC) compared to daratumumab.","method":"Co-crystallization of HexaBody-CD38 with CD38, fluorescence spectroscopy for cyclase inhibition, CDC/ADCC/ADCP/apoptosis flow cytometry assays, patient-derived xenograft mouse models","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — crystal structure defines epitope, direct enzymatic inhibition assay, multiple effector mechanism assays, in vivo xenograft validation","pmids":["37379657"],"is_preprint":false},{"year":2011,"finding":"In vitro activation of CLL cells through CD38 drives proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2, establishing CD38 as a functional signal transducer promoting CLL cell survival and migration.","method":"CD38 ligation assays in CLL cells, Western blotting of ZAP-70 and ERK1/2 phosphorylation, proliferation and chemotaxis assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct signaling assays linking CD38 ligation to defined kinase pathway and functional readouts, replicated across multiple CLL studies","pmids":["21765022"],"is_preprint":false},{"year":2001,"finding":"Human monocytes rapidly degrade extracellular NAD+ to nicotinamide and ADP-ribose via surface CD38 (NAD+-glycohydrolase activity). Anti-CD38 mAb ligation induces CD38 internalization and shedding. Monocyte-to-macrophage differentiation downregulates surface CD38 expression at the transcriptional level, correlating with reduced NADase activity.","method":"NAD+ degradation product analysis (HPLC), flow cytometry, RT-PCR, anti-CD38 mAb internalization assays, monocyte-to-macrophage differentiation experiments","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct NADase activity measurement linked to CD38 expression level, internalization demonstrated, transcriptional regulation identified, single lab","pmids":["11683883"],"is_preprint":false},{"year":2016,"finding":"CD38 knockout mice exhibit deficits in spatial memory (Morris water maze), contextual fear conditioning, and object recognition memory. However, hippocampal long-term potentiation and long-term depression are intact in CD38−/− mice, indicating CD38 is required for hippocampus-dependent learning and memory through mechanisms independent of synaptic plasticity.","method":"Morris water maze, contextual fear conditioning, object recognition tests in CD38−/− mice, electrophysiological LTP/LTD recordings in hippocampal slices","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with multiple behavioral paradigms and electrophysiology controls, single lab, specific mechanistic dissociation","pmids":["26856703"],"is_preprint":false}],"current_model":"CD38 is a multifunctional type II transmembrane glycoprotein that acts as a bifunctional ectoenzyme catalyzing synthesis and hydrolysis of cyclic ADP-ribose (cADPR) and NAADP from NAD(P)+, primarily depleting cellular NAD+ pools; it exists in two opposing membrane orientations (type II extracellular and type III intracellular catalytic domain), with the type III orientation driving intracellular cADPR accumulation and Ca2+ signaling; NAADP is produced specifically in the endolysosomal compartment upon CD38 internalization; as a receptor, CD38 signals through lineage-specific co-association with professional signaling molecules (e.g., CD16 in NK cells) to activate ZAP-70, MAPK, and Ca2+ cascades, and is recruited to the immunological synapse via Lck-dependent mechanisms to modulate PKCθ and cytokine production; CD38-mediated NAD+ depletion regulates macrophage inflammatory cytokine production, T cell metabolism, cardiac hypertrophy via SIRT3/Ca2+-NFAT signaling, and tissue aging across multiple organ systems."},"narrative":{"mechanistic_narrative":"CD38 is a multifunctional type II transmembrane glycoprotein that acts both as a bifunctional ectoenzyme and as a lineage-specific signaling receptor, coupling NAD(P)+ metabolism to calcium signaling, immune activation, and tissue NAD+ homeostasis [PMID:8903511, PMID:11895784, PMID:33199924]. Enzymatically, CD38 catalyzes the synthesis and hydrolysis of the Ca2+-mobilizing second messenger cyclic ADP-ribose, acting independently of inositol trisphosphate, and also degrades extracellular NAD+ to nicotinamide and ADP-ribose via its NAD+-glycohydrolase activity [PMID:8903511, PMID:7875731, PMID:11683883]. A topological feature underlies its second-messenger function: CD38 occupies two opposing membrane orientations, and the type III orientation (catalytic domain facing the cytosol) drives intracellular cADPR accumulation and Ca2+ signaling [PMID:22969159]. For NAADP, in vivo CD38 functions chiefly as a degrading rather than synthesizing enzyme, and NAADP production is controlled by compartmentalization: clathrin-dependent internalization delivers CD38 to the endolysosome where substrate access raises NAADP levels [PMID:22020217, PMID:29632067]. As a receptor, CD38 signals through co-association with professional signaling molecules—physically associating with CD16 (FcγRIIIA) in NK cells to drive ZAP-70/MAPK phosphorylation, Ca2+ flux, and cytokine secretion, and binding CD31 (PECAM-1) to mediate leukocyte adhesion [PMID:11895784, PMID:11137554]. CD38 is recruited to the immunological synapse in an antigen- and Lck-dependent manner from both plasma-membrane and recycling-endosome pools, modulating PKCθ activation and IL-2/IFN-γ production [PMID:18212246]. Across multiple tissues, CD38-mediated NAD+ depletion is a central driver of pathology: its NADase activity arrests prostate cancer cell metabolism, inflammatory macrophages upregulate CD38 to lower tissue NAD+ during aging, and CD38 loss is protective in cardiac hypertrophy, lung fibrosis, osteoarthritis, and ovarian reserve depletion via NAD+- and SIRT-dependent mechanisms [PMID:30076241, PMID:33199924, PMID:28296029, PMID:35687485, PMID:36103412, PMID:37822499]. Catalytic-mutant controls establish that NADase activity, not receptor function, underlies these metabolic effects [PMID:30076241, PMID:30258629]. Structurally characterized epitopes on the catalytic domain underpin therapeutic anti-CD38 antibodies that act by cell depletion, cyclase/ecto-enzyme inhibition that boosts NAD+ and sirtuin activity, or dynamin-dependent CD38 internalization [PMID:27251573, PMID:35867844, PMID:37379657, PMID:30288349].","teleology":[{"year":1994,"claim":"Established that CD38 receptor ligation transduces signals through a non-canonical pathway, distinguishing it from classical PLC-coupled receptors.","evidence":"Calcium flux, inositol phosphate, and tyrosine phosphorylation assays in murine B cells with anti-CD38 antibody","pmids":["7875731"],"confidence":"Medium","gaps":["Did not identify the kinases or co-receptors mediating the tyrosine phosphorylation","No direct link to a downstream functional output"]},{"year":1996,"claim":"Defined CD38 as a bifunctional ectoenzyme producing and degrading the Ca2+-mobilizing messenger cADPR, reframing it from a pure surface marker to a metabolic enzyme.","evidence":"Biochemical ectoenzyme assays and antibody-ligation/internalization studies in hematopoietic cells","pmids":["8903511"],"confidence":"High","gaps":["Did not resolve how an ectoenzyme generates an intracellular messenger (topological paradox)","Receptor versus enzyme contributions not separated"]},{"year":1997,"claim":"Proposed resolutions to the topological paradox—cADPR transport across the membrane and NAD+-induced CD38 internalization—addressing how surface enzyme activity reaches intracellular stores.","evidence":"Biochemical fractionation and NAD+-induced internalization experiments in lymphoid B cells","pmids":["9438379"],"confidence":"Medium","gaps":["Two mechanisms with partial support; relative contributions unresolved","Transport route for extracellular cADPR not molecularly defined"]},{"year":2001,"claim":"Identified the receptor partners and downstream signaling required for CD38 to drive NK and leukocyte function, showing CD38 needs CD16 as a co-signaling partner and binds CD31 for adhesion.","evidence":"Genetic complementation of CD16-negative NK lines, signaling/cytokine assays, and CD38–CD31 binding/adhesion assays","pmids":["11282979","11137554"],"confidence":"Medium","gaps":["Molecular nature of the CD38–CD16 physical interaction not yet shown","CD31 binding affinity and stoichiometry not defined"]},{"year":2001,"claim":"Linked CD38 surface NADase activity to expression level and internalization in monocytes, connecting enzyme function to cell differentiation state.","evidence":"HPLC NAD+ degradation product analysis, flow cytometry, RT-PCR, and differentiation experiments in human monocytes","pmids":["11683883"],"confidence":"Medium","gaps":["Functional consequence of NAD+ depletion for monocyte biology not addressed","Mechanism of transcriptional downregulation during differentiation unknown"]},{"year":2002,"claim":"Demonstrated direct physical association of CD38 with CD16 and that CD16 is necessary and sufficient for CD38-driven NK activation, establishing the co-association model of CD38 receptor signaling.","evidence":"FRET and cocapping with functional Ca2+/phosphorylation/cytokine/cytotoxicity readouts in CD16+/- NK variants","pmids":["11895784"],"confidence":"High","gaps":["Whether other lineages use distinct co-receptors not tested here","Enzyme activity contribution to NK signaling not separated from receptor function"]},{"year":2008,"claim":"Showed CD38 is recruited to the immunological synapse via Lck-dependent signals from membrane and recycling-endosome pools to amplify Ca2+ and modulate PKCθ and cytokine output in T cells.","evidence":"Confocal/live imaging of CD38-GFP, siRNA knockdown, Ca2+ flux, ELISA, and PKCθ phosphorylation in human T and B cells","pmids":["18212246"],"confidence":"High","gaps":["Receptor that triggers CD38 redistribution not identified","Whether enzymatic activity is required for synapse function unresolved"]},{"year":2011,"claim":"Refined CD38's NAADP role, showing it acts in vivo as a NAADP-degrading rather than synthesizing enzyme, implying it limits desensitizing NAADP accumulation.","evidence":"siRNA silencing and CD38 KO mouse tissues versus in vitro enzymatic NAADP formation/degradation assays","pmids":["22020217"],"confidence":"Medium","gaps":["Identity of the in vivo NAADP synthase left open","Reconciliation with later compartmentalized NAADP production needed"]},{"year":2011,"claim":"Connected CD38 expression to immune-regulatory and tumor signaling, marking highly suppressive Tregs downstream of PI3K p110δ and driving CLL proliferation/chemotaxis via ZAP-70/ERK.","evidence":"p110δ(D910A) Treg transcriptomics/suppression assays and CD38-ligation signaling/proliferation assays in CLL cells","pmids":["21390257","21765022"],"confidence":"Medium","gaps":["Whether CD38 enzymatic vs receptor activity drives these phenotypes unclear","Direct receptor partners in CLL not defined"]},{"year":2012,"claim":"Resolved the topological paradox at the molecular level by demonstrating two opposing membrane orientations, with the type III (cytosol-facing catalytic) orientation enabling intracellular cADPR/Ca2+ signaling.","evidence":"Orientation-specific antibodies, site-directed mutagenesis of N-terminal cationic residues, and intracellular cADPR measurement in multiple cell types","pmids":["22969159"],"confidence":"High","gaps":["Mechanism determining orientation choice during biogenesis unknown","Physiological proportion of type III in primary cells not quantified"]},{"year":2012,"claim":"Defined inflammatory regulation of CD38, with LPS inducing CD38 transcription via JAK-STAT and MMP-9 shedding releasing soluble CD38.","evidence":"RT-PCR, JAK-STAT and MMP-9 inhibitor studies, and ELISA for soluble CD38 in J774 macrophages","pmids":["23184288"],"confidence":"Medium","gaps":["Function of shed soluble CD38 not established","STAT transcription factor identity not pinned down"]},{"year":2016,"claim":"Provided structural epitope maps of the CD38 catalytic domain and proof-of-concept that targeting it selectively kills malignant cells.","evidence":"X-ray crystallography of CD38–nanobody complexes and immunotoxin cytotoxicity against multiple myeloma cells","pmids":["27251573"],"confidence":"High","gaps":["Structures did not address membrane orientation or full-length context","Enzymatic effect of epitope binding not measured"]},{"year":2018,"claim":"Established that CD38 NADase activity—not receptor signaling—drives metabolic reprogramming, depleting intracellular and extracellular NAD+ to arrest cell cycle and metabolism, using catalytic-dead mutant controls.","evidence":"CD38 overexpression with NADase-deficient mutant, NAD+ measurement, Seahorse flux, cell-cycle and AMPK assays, plus KO mouse tissue NAD+ in prostate models","pmids":["30076241","30258629"],"confidence":"High","gaps":["Whether type II vs type III orientation governs intracellular NAD+ depletion not addressed","Source NAD+ pool (cytosolic vs extracellular import) for intracellular effects not fully resolved"]},{"year":2018,"claim":"Showed CD38 NAADP production is governed by subcellular localization, with clathrin/lysosome targeting—not enzyme activation—setting NAADP output.","evidence":"Nanobody-directed endocytosis, lysosome-targeted CD38 constructs, clathrin inhibition, and intracellular NAADP measurement in human cells","pmids":["29632067"],"confidence":"High","gaps":["Physiological trigger for endogenous CD38 lysosomal trafficking not identified","Link between lysosomal NAADP and specific Ca2+ channels not shown here"]},{"year":2018,"claim":"Defined CD38 as an inducible amplifier of macrophage inflammation, required for IL-6/IL-12p40 secretion and glycolysis under classical activation.","evidence":"LPS/IFN-γ/IL-4 stimulation with siRNA and pharmacological CD38 inhibition and cytokine/glycolysis assays in primary human macrophages","pmids":["30042766"],"confidence":"Medium","gaps":["Whether enzymatic NAD+ depletion mediates the cytokine effect not separated","Downstream metabolic node linking CD38 to glycolysis undefined"]},{"year":2018,"claim":"Clarified mechanisms of anti-CD38 therapeutics, showing daratumumab induces dynamin/clathrin-dependent CD38 internalization and degradation that reshapes NK/monocyte function and impairs MM adhesion to sensitize to bortezomib.","evidence":"Flow cytometry of surface CD38 after daratumumab, Dynasore rescue of adhesion, monocyte activation/phagocytosis and bortezomib combination assays in vitro and in vivo","pmids":["32296125","30288349"],"confidence":"Medium","gaps":["Adapter machinery driving antibody-induced internalization not fully defined","Relative contribution of internalization vs effector killing in patients unclear"]},{"year":2017,"claim":"Implicated CD38 NAD+ depletion in cardiac disease, linking it to SIRT3 suppression and Ca2+-NFAT signaling in angiotensin II-induced hypertrophy.","evidence":"CD38 KO mice with Ang-II infusion, cardiac histology, and RNAi knockdown with signaling readouts in H9c2 cardiomyocytes","pmids":["28296029"],"confidence":"Medium","gaps":["Direct demonstration that NADase activity (not receptor) drives the SIRT3 axis not shown","Cell type responsible (cardiomyocyte vs infiltrating cells) in vivo not isolated"]},{"year":2019,"claim":"Extended CD38 signaling control to B-cell receptor pathways in CLL and showed daratumumab can directly trigger FcγR-dependent apoptosis.","evidence":"Immunoblotting of Syk/BTK/PLCγ2/ERK/AKT after CD38 targeting, apoptosis and FcγR-blocking assays, and CLL xenografts","pmids":["30940652"],"confidence":"Medium","gaps":["Mechanistic coupling of CD38 to the BCR module not structurally defined","Whether ectoenzyme activity participates not tested"]},{"year":2020,"claim":"Defined feedback and aging circuits of CD38 NADase, with a CD38–TTP–Sirt1 loop resolving sepsis inflammation and senescence-driven macrophage CD38 induction lowering tissue NAD+ during aging.","evidence":"Sepsis models with CD38/TTP KO and Sirt1 inhibition; tissue macrophage NADase activity, SASP induction, and senescent cell depletion in aged mice","pmids":["31995750","33199924"],"confidence":"High","gaps":["Receptors/transcription factors linking SASP to CD38 induction incompletely mapped","Whether other NAD-consuming enzymes contribute to tissue decline not excluded"]},{"year":2022,"claim":"Linked CD38-driven NAD+ loss to oxidative damage and ferroptosis, with high CD38 raising ROS and causing Cys7-sulfonation-dependent DHFR degradation rescuable by NAD+ precursor.","evidence":"CD38 overexpression, ROS measurement, DHFR Cys7 mutagenesis, autophagy/proteasome inhibitors, ferroptosis assays, and NMN rescue","pmids":["36351893"],"confidence":"Medium","gaps":["Direct enzymatic-mutant control for CD38 NADase in this pathway not described","Generality across cell types beyond macrophages unclear"]},{"year":2022,"claim":"Generalized CD38 NAD+ depletion as a driver of tissue fibrosis and aging, with CD38 elevation in alveolar epithelial cells promoting senescence and lung fibrosis.","evidence":"scRNA-seq, CD38 KO and pharmacological inhibition, NAD+ measurement, and bleomycin fibrosis model in mice","pmids":["35687485"],"confidence":"Medium","gaps":["Catalytic-mutant proof in epithelium not provided","Trigger of CD38 elevation in AECs not defined"]},{"year":2022,"claim":"Demonstrated therapeutic enzyme inhibition without cell killing as a distinct anti-CD38 strategy, with a biparatopic Fc-silenced antibody inhibiting ecto-enzyme activity and boosting NAD+ and sirtuin activity.","evidence":"Fluorescence enzymatic assays, intracellular NAD+ and sirtuin activity measurement, SPR binding, and ADCC/CDC assays for TNB-738","pmids":["35867844"],"confidence":"Medium","gaps":["In vivo NAD+ restoration efficacy not detailed here","Durability of enzyme inhibition not addressed"]},{"year":2023,"claim":"Combined structural epitope definition with dual therapeutic mechanism, showing a HexaBody antibody inhibits CD38 cyclase activity while Fc hexamerization potentiates complement-dependent killing.","evidence":"Co-crystallization, cyclase inhibition spectroscopy, CDC/ADCC/ADCP/apoptosis assays, and patient-derived xenografts","pmids":["37379657"],"confidence":"High","gaps":["Whether cyclase inhibition contributes clinically beyond killing not resolved","Epitope effect on type III orientation not examined"]},{"year":2023,"claim":"Extended CD38 NAD+ consumption to reproductive aging and joint disease, with CD38 loss enlarging ovarian reserve and protecting cartilage after injury via raised NAD+.","evidence":"CD38 KO mouse ovarian phenotyping/NAD+ measurement and chondrocyte gain/loss-of-function with NAD+:NADH measurement plus DMM joint injury model","pmids":["37822499","36103412"],"confidence":"Medium","gaps":["Cell-autonomous vs systemic NAD+ effects not fully separated","Whether receptor signaling contributes alongside NADase not addressed"]},{"year":2016,"claim":"Revealed a neurological requirement for CD38 in learning and memory that is independent of classical synaptic plasticity.","evidence":"Behavioral testing (water maze, fear conditioning, object recognition) and hippocampal LTP/LTD electrophysiology in CD38 KO mice","pmids":["26856703"],"confidence":"Medium","gaps":["Molecular mediator (cADPR/Ca2+ vs oxytocin-related signaling) not identified here","Brain cell type responsible not localized"]},{"year":null,"claim":"How the determinants of CD38 membrane orientation and subcellular trafficking are physiologically regulated to dictate when CD38 depletes NAD+ versus generates compartmentalized Ca2+ messengers remains unresolved.","evidence":"No timeline discovery defines the in vivo signals controlling type II/III orientation choice or endolysosomal targeting","pmids":[],"confidence":"Low","gaps":["Biogenic mechanism setting orientation unknown","Endogenous trigger for lysosomal trafficking undefined","Integration of enzyme vs receptor roles in a single cell not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,7,8,16,30]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,16,30]},{"term_id":"GO:0009975","term_label":"cyclase activity","supporting_discovery_ids":[0,28]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,4,5]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,30]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[8]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[5,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,16]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,4,5,18,19]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,17,18,23,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,29]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[18,26]}],"complexes":[],"partners":["CD16","CD31"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28907","full_name":"ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1","aliases":["2'-phospho-ADP-ribosyl cyclase","2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase","2'-phospho-cyclic-ADP-ribose transferase","ADP-ribosyl cyclase 1","ADPRC 1","Cyclic ADP-ribose hydrolase 1","cADPR hydrolase 1","T10"],"length_aa":300,"mass_kda":34.3,"function":"Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed:7961800, PubMed:8253715). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed:16690024). Has cADPR hydrolase activity (PubMed:7961800, PubMed:8253715). Functions also as a receptor that binds the ligand CD31 on endothelial cells, promoting lymphocyte activation, proliferation, and migration across the endothelial barrier (PubMed:9551996). Involved in the regulation of crucial dendritic cell functions acquired at the mature stage, such as CCL21-driven migration, survival, and Th1-polarizing activity (PubMed:16293598). In lamina propria T lymphocytes, CD38/CD31 cognate interactions initiate a multistep signaling pathway resulting in activation of LCK anf LAT, followed by cytokine release (PubMed:11259373)","subcellular_location":"Cell surface; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P28907/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD38","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD38","total_profiled":1310},"omim":[{"mim_id":"620778","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, SHORT CYTOPLASMIC TAIL, 1; KIR3DS1","url":"https://www.omim.org/entry/620778"},{"mim_id":"615513","title":"IMMUNODEFICIENCY 14A WITH LYMPHOPROLIFERATION, AUTOSOMAL DOMINANT; IMD14A","url":"https://www.omim.org/entry/615513"},{"mim_id":"612760","title":"SNF-RELATED KINASE; SNRK","url":"https://www.omim.org/entry/612760"},{"mim_id":"610116","title":"PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 14; P2RY14","url":"https://www.omim.org/entry/610116"},{"mim_id":"608628","title":"TRANSDUCIN-BETA-LIKE 1 RECEPTOR 1; TBL1XR1","url":"https://www.omim.org/entry/608628"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":58.9}],"url":"https://www.proteinatlas.org/search/CD38"},"hgnc":{"alias_symbol":["cADPR1"],"prev_symbol":[]},"alphafold":{"accession":"P28907","domains":[{"cath_id":"3.40.50.720","chopping":"54-297","consensus_level":"medium","plddt":95.6905,"start":54,"end":297}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28907","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28907-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28907-F1-predicted_aligned_error_v6.png","plddt_mean":90.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD38","jax_strain_url":"https://www.jax.org/strain/search?query=CD38"},"sequence":{"accession":"P28907","fasta_url":"https://rest.uniprot.org/uniprotkb/P28907.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28907/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28907"}},"corpus_meta":[{"pmid":"26308596","id":"PMC_26308596","title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.","date":"2015","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26308596","citation_count":948,"is_preprint":false},{"pmid":"29118010","id":"PMC_29118010","title":"CD38 antibodies in multiple myeloma: back to the future.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29118010","citation_count":388,"is_preprint":false},{"pmid":"33199924","id":"PMC_33199924","title":"Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33199924","citation_count":352,"is_preprint":false},{"pmid":"26864107","id":"PMC_26864107","title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.","date":"2016","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26864107","citation_count":282,"is_preprint":false},{"pmid":"33329591","id":"PMC_33329591","title":"CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33329591","citation_count":265,"is_preprint":false},{"pmid":"32937047","id":"PMC_32937047","title":"Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.","date":"2020","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32937047","citation_count":263,"is_preprint":false},{"pmid":"8903511","id":"PMC_8903511","title":"Human CD38, a cell-surface protein with multiple functions.","date":"1996","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/8903511","citation_count":260,"is_preprint":false},{"pmid":"23576305","id":"PMC_23576305","title":"CD38 and CD157: a long journey from activation markers to multifunctional molecules.","date":"2013","source":"Cytometry. Part B, Clinical cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/23576305","citation_count":230,"is_preprint":false},{"pmid":"11137554","id":"PMC_11137554","title":"Human CD38: a (r)evolutionary story of enzymes and receptors.","date":"2001","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/11137554","citation_count":227,"is_preprint":false},{"pmid":"11675331","id":"PMC_11675331","title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11675331","citation_count":202,"is_preprint":false},{"pmid":"12149224","id":"PMC_12149224","title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12149224","citation_count":189,"is_preprint":false},{"pmid":"29482842","id":"PMC_29482842","title":"The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.","date":"2018","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29482842","citation_count":182,"is_preprint":false},{"pmid":"18326821","id":"PMC_18326821","title":"CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18326821","citation_count":176,"is_preprint":false},{"pmid":"30042766","id":"PMC_30042766","title":"CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30042766","citation_count":175,"is_preprint":false},{"pmid":"21765022","id":"PMC_21765022","title":"CD38 and chronic lymphocytic leukemia: a decade later.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21765022","citation_count":171,"is_preprint":false},{"pmid":"22969159","id":"PMC_22969159","title":"The membrane-bound enzyme CD38 exists in two opposing orientations.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22969159","citation_count":142,"is_preprint":false},{"pmid":"30546360","id":"PMC_30546360","title":"CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30546360","citation_count":140,"is_preprint":false},{"pmid":"31779273","id":"PMC_31779273","title":"Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31779273","citation_count":120,"is_preprint":false},{"pmid":"32085567","id":"PMC_32085567","title":"CD38 in Neurodegeneration and Neuroinflammation.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32085567","citation_count":114,"is_preprint":false},{"pmid":"31963337","id":"PMC_31963337","title":"Roles of CD38 in the Immune Response to Infection.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31963337","citation_count":111,"is_preprint":false},{"pmid":"29483513","id":"PMC_29483513","title":"Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29483513","citation_count":108,"is_preprint":false},{"pmid":"33375774","id":"PMC_33375774","title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.","date":"2022","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/33375774","citation_count":98,"is_preprint":false},{"pmid":"7576049","id":"PMC_7576049","title":"Murine CD38: an immunoregulatory ectoenzyme.","date":"1995","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7576049","citation_count":93,"is_preprint":false},{"pmid":"11895784","id":"PMC_11895784","title":"Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11895784","citation_count":92,"is_preprint":false},{"pmid":"22227279","id":"PMC_22227279","title":"CD38 and its role in oxytocin secretion and social behavior.","date":"2011","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/22227279","citation_count":82,"is_preprint":false},{"pmid":"21390257","id":"PMC_21390257","title":"The PI3K p110δ regulates expression of CD38 on regulatory T cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21390257","citation_count":78,"is_preprint":false},{"pmid":"38129670","id":"PMC_38129670","title":"NADase CD38 is a key determinant of ovarian aging.","date":"2023","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/38129670","citation_count":75,"is_preprint":false},{"pmid":"32709019","id":"PMC_32709019","title":"CD38: T Cell Immuno-Metabolic Modulator.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32709019","citation_count":75,"is_preprint":false},{"pmid":"29702148","id":"PMC_29702148","title":"Immunomodulatory effects of CD38-targeting antibodies.","date":"2018","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29702148","citation_count":75,"is_preprint":false},{"pmid":"18212246","id":"PMC_18212246","title":"Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18212246","citation_count":73,"is_preprint":false},{"pmid":"9438379","id":"PMC_9438379","title":"The CD38/cyclic ADP-ribose system: a topological paradox.","date":"1997","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9438379","citation_count":71,"is_preprint":false},{"pmid":"11282979","id":"PMC_11282979","title":"Signaling through CD38 induces NK cell activation.","date":"2001","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11282979","citation_count":71,"is_preprint":false},{"pmid":"32296125","id":"PMC_32296125","title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.","date":"2020","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/32296125","citation_count":71,"is_preprint":false},{"pmid":"28296029","id":"PMC_28296029","title":"CD38 promotes angiotensin II-induced cardiac hypertrophy.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28296029","citation_count":70,"is_preprint":false},{"pmid":"35834988","id":"PMC_35834988","title":"CD38: An important regulator of T cell function.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/35834988","citation_count":68,"is_preprint":false},{"pmid":"10088597","id":"PMC_10088597","title":"The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10088597","citation_count":66,"is_preprint":false},{"pmid":"10395373","id":"PMC_10395373","title":"Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors.","date":"1999","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/10395373","citation_count":65,"is_preprint":false},{"pmid":"35251964","id":"PMC_35251964","title":"CD38: A Significant Regulator of Macrophage Function.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35251964","citation_count":63,"is_preprint":false},{"pmid":"35138178","id":"PMC_35138178","title":"The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.","date":"2022","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35138178","citation_count":62,"is_preprint":false},{"pmid":"33727923","id":"PMC_33727923","title":"CD38 and Regulation of the Immune Response Cells in Cancer.","date":"2021","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33727923","citation_count":61,"is_preprint":false},{"pmid":"27251573","id":"PMC_27251573","title":"Immuno-targeting the multifunctional CD38 using nanobody.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27251573","citation_count":61,"is_preprint":false},{"pmid":"35687485","id":"PMC_35687485","title":"CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging.","date":"2022","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35687485","citation_count":59,"is_preprint":false},{"pmid":"30288349","id":"PMC_30288349","title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30288349","citation_count":59,"is_preprint":false},{"pmid":"23335873","id":"PMC_23335873","title":"The roles of oxytocin and CD38 in social or parental behaviors.","date":"2013","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23335873","citation_count":52,"is_preprint":false},{"pmid":"30076241","id":"PMC_30076241","title":"CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30076241","citation_count":50,"is_preprint":false},{"pmid":"26856703","id":"PMC_26856703","title":"Impaired learning and memory in CD38 null mutant mice.","date":"2016","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/26856703","citation_count":48,"is_preprint":false},{"pmid":"34095875","id":"PMC_34095875","title":"Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways.","date":"2021","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34095875","citation_count":48,"is_preprint":false},{"pmid":"12415565","id":"PMC_12415565","title":"CD157, the Janus of CD38 but with a unique personality.","date":"2002","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/12415565","citation_count":46,"is_preprint":false},{"pmid":"7875731","id":"PMC_7875731","title":"Murine B-cell activation via CD38 and protein tyrosine phosphorylation.","date":"1994","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7875731","citation_count":46,"is_preprint":false},{"pmid":"31881755","id":"PMC_31881755","title":"CD38, CD157, and RAGE as Molecular Determinants for Social Behavior.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31881755","citation_count":41,"is_preprint":false},{"pmid":"32331242","id":"PMC_32331242","title":"Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32331242","citation_count":41,"is_preprint":false},{"pmid":"19052657","id":"PMC_19052657","title":"CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.","date":"2008","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/19052657","citation_count":41,"is_preprint":false},{"pmid":"37840445","id":"PMC_37840445","title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.","date":"2023","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37840445","citation_count":39,"is_preprint":false},{"pmid":"7734417","id":"PMC_7734417","title":"CD38 expression on mouse T cells: CD38 defines functionally distinct subsets of alpha beta TCR+CD4-CD8- thymocytes.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7734417","citation_count":38,"is_preprint":false},{"pmid":"22020217","id":"PMC_22020217","title":"CD38: a NAADP degrading enzyme.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22020217","citation_count":37,"is_preprint":false},{"pmid":"30940652","id":"PMC_30940652","title":"Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30940652","citation_count":37,"is_preprint":false},{"pmid":"29632067","id":"PMC_29632067","title":"CD38 produces nicotinic acid adenosine dinucleotide phosphate in the lysosome.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29632067","citation_count":37,"is_preprint":false},{"pmid":"32612286","id":"PMC_32612286","title":"CD38 in cancer-associated fibroblasts promotes pro-tumoral activity.","date":"2020","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32612286","citation_count":35,"is_preprint":false},{"pmid":"10064783","id":"PMC_10064783","title":"Characterization and localization of CD38 in the vertebrate eye.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10064783","citation_count":35,"is_preprint":false},{"pmid":"33678520","id":"PMC_33678520","title":"CD38 in Advanced Prostate Cancers.","date":"2021","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/33678520","citation_count":34,"is_preprint":false},{"pmid":"37180151","id":"PMC_37180151","title":"CD38: an ecto-enzyme with functional diversity in T cells.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37180151","citation_count":34,"is_preprint":false},{"pmid":"27999737","id":"PMC_27999737","title":"Immunotherapies targeting CD38 in Multiple Myeloma.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27999737","citation_count":34,"is_preprint":false},{"pmid":"31995750","id":"PMC_31995750","title":"Cross-talk between CD38 and TTP Is Essential for Resolution of Inflammation during Microbial Sepsis.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31995750","citation_count":34,"is_preprint":false},{"pmid":"23686525","id":"PMC_23686525","title":"CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23686525","citation_count":34,"is_preprint":false},{"pmid":"27939939","id":"PMC_27939939","title":"CD38 in the pathogenesis of allergic airway disease: Potential therapeutic targets.","date":"2016","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27939939","citation_count":33,"is_preprint":false},{"pmid":"31842517","id":"PMC_31842517","title":"The Anti-CD38 Antibody Therapy in Multiple Myeloma.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31842517","citation_count":32,"is_preprint":false},{"pmid":"30394809","id":"PMC_30394809","title":"CD38 as an immunotherapeutic target in multiple myeloma.","date":"2018","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30394809","citation_count":32,"is_preprint":false},{"pmid":"17380203","id":"PMC_17380203","title":"CD38 as a therapeutic target.","date":"2006","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/17380203","citation_count":31,"is_preprint":false},{"pmid":"30258629","id":"PMC_30258629","title":"CD38 is methylated in prostate cancer and regulates extracellular NAD.","date":"2018","source":"Cancer & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30258629","citation_count":31,"is_preprint":false},{"pmid":"35765110","id":"PMC_35765110","title":"Expanding anti-CD38 immunotherapy for lymphoid malignancies.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35765110","citation_count":30,"is_preprint":false},{"pmid":"37485647","id":"PMC_37485647","title":"CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37485647","citation_count":30,"is_preprint":false},{"pmid":"11683883","id":"PMC_11683883","title":"NAD degradation and regulation of CD38 expression by human monocytes/macrophages.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11683883","citation_count":30,"is_preprint":false},{"pmid":"33820568","id":"PMC_33820568","title":"The role of CD38 in HIV infection.","date":"2021","source":"AIDS research and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33820568","citation_count":29,"is_preprint":false},{"pmid":"23184288","id":"PMC_23184288","title":"Lipopolysaccharide induces CD38 expression and solubilization in J774 macrophage cells.","date":"2012","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/23184288","citation_count":29,"is_preprint":false},{"pmid":"28573863","id":"PMC_28573863","title":"CD38 as a PET Imaging Target in Lung Cancer.","date":"2017","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/28573863","citation_count":29,"is_preprint":false},{"pmid":"29772458","id":"PMC_29772458","title":"Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29772458","citation_count":29,"is_preprint":false},{"pmid":"35342342","id":"PMC_35342342","title":"Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35342342","citation_count":28,"is_preprint":false},{"pmid":"36077708","id":"PMC_36077708","title":"Targeting CD38 in Neoplasms and Non-Cancer Diseases.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36077708","citation_count":27,"is_preprint":false},{"pmid":"33467713","id":"PMC_33467713","title":"IFN-γ and CD38 in Hyperprogressive Cancer Development.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33467713","citation_count":27,"is_preprint":false},{"pmid":"24389178","id":"PMC_24389178","title":"CD38 and bone marrow microenvironment.","date":"2014","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/24389178","citation_count":26,"is_preprint":false},{"pmid":"32857612","id":"PMC_32857612","title":"CD38 as an immunomodulator in cancer.","date":"2020","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32857612","citation_count":26,"is_preprint":false},{"pmid":"38608514","id":"PMC_38608514","title":"Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38608514","citation_count":26,"is_preprint":false},{"pmid":"35093485","id":"PMC_35093485","title":"CD38+ B cells affect immunotherapy for allergic rhinitis.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35093485","citation_count":26,"is_preprint":false},{"pmid":"36103412","id":"PMC_36103412","title":"Targeting CD38 to Suppress Osteoarthritis Development and Associated Pain After Joint Injury in Mice.","date":"2023","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/36103412","citation_count":26,"is_preprint":false},{"pmid":"32360414","id":"PMC_32360414","title":"A Novel Role of CD38 and Oxytocin as Tandem Molecular Moderators of Human Social Behavior.","date":"2020","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32360414","citation_count":26,"is_preprint":false},{"pmid":"37379657","id":"PMC_37379657","title":"Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.","date":"2023","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37379657","citation_count":25,"is_preprint":false},{"pmid":"39358361","id":"PMC_39358361","title":"The frequency of CD38+ alveolar macrophages correlates with early control of M. tuberculosis in the murine lung.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39358361","citation_count":24,"is_preprint":false},{"pmid":"32531894","id":"PMC_32531894","title":"CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32531894","citation_count":24,"is_preprint":false},{"pmid":"21901817","id":"PMC_21901817","title":"CD38 through the life of a murine B lymphocyte.","date":"2011","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/21901817","citation_count":24,"is_preprint":false},{"pmid":"33570193","id":"PMC_33570193","title":"Molecular dynamics of targeting CD38 in multiple myeloma.","date":"2021","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/33570193","citation_count":24,"is_preprint":false},{"pmid":"30535454","id":"PMC_30535454","title":"CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30535454","citation_count":24,"is_preprint":false},{"pmid":"37822499","id":"PMC_37822499","title":"CD38 regulates ovarian function and fecundity via NAD+ metabolism.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37822499","citation_count":23,"is_preprint":false},{"pmid":"33010451","id":"PMC_33010451","title":"CD38 downregulation modulates NAD+ and NADP(H) levels in thermogenic adipose tissues.","date":"2020","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/33010451","citation_count":23,"is_preprint":false},{"pmid":"15505998","id":"PMC_15505998","title":"CD38 autoimmunity: recent advances and relevance to human diabetes.","date":"2004","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15505998","citation_count":22,"is_preprint":false},{"pmid":"30537007","id":"PMC_30537007","title":"HIV Disease Progression: Overexpression of the Ectoenzyme CD38 as a Contributory Factor?","date":"2018","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/30537007","citation_count":22,"is_preprint":false},{"pmid":"39501292","id":"PMC_39501292","title":"CD38 as theranostic target in oncology.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39501292","citation_count":21,"is_preprint":false},{"pmid":"30915370","id":"PMC_30915370","title":"Increased TLR4 Expression Aggravates Sepsis by Promoting IFN-γ Expression in CD38-/- Mice.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30915370","citation_count":21,"is_preprint":false},{"pmid":"35867844","id":"PMC_35867844","title":"TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.","date":"2022","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/35867844","citation_count":20,"is_preprint":false},{"pmid":"29582696","id":"PMC_29582696","title":"Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.","date":"2018","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29582696","citation_count":19,"is_preprint":false},{"pmid":"36351893","id":"PMC_36351893","title":"Oxidative degradation of dihydrofolate reductase increases CD38-mediated ferroptosis susceptibility.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36351893","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47271,"output_tokens":8429,"usd":0.134124,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18578,"output_tokens":7788,"usd":0.143795,"stage2_stop_reason":"end_turn"},"total_usd":0.277919,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CD38 functions as a bifunctional ectoenzyme that catalyzes both the synthesis and hydrolysis of cyclic ADP-ribose (cADPR), a Ca2+-mobilizing second messenger acting independently of inositol trisphosphate. It also functions as a receptor capable of mediating transmembrane signals and can be internalized in response to appropriate stimuli.\",\n      \"method\": \"Biochemical ectoenzyme assays, internalization experiments, functional antibody ligation studies in hematopoietic cells\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — enzymatic activity reconstituted biochemically, replicated across multiple labs and cell types, foundational mechanistic characterization\",\n      \"pmids\": [\"8903511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The topological paradox of CD38's ectocellular catalytic domain synthesizing the intracellular messenger cADPR may be resolved by two mechanisms: (a) influx of extracellular cADPR across the plasma membrane to reach ryanodine-sensitive intracellular stores, and (b) NAD+-induced internalization of CD38 following membrane oligomerization, importing cADPR metabolism to an intracellular compartment, as observed in lymphoid B cells.\",\n      \"method\": \"Biochemical fractionation, NAD+-induced internalization experiments in lymphoid B cells, cerebellar granule cell Ca2+ signaling studies\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct internalization experiments in B cells, single lab, two proposed mechanisms with partial experimental support\",\n      \"pmids\": [\"9438379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD38 ligation on murine B cells stimulates protein tyrosine kinase activity but does not mobilize intracellular calcium stores and is not coupled to generation of inositol phosphates, indicating CD38 signals through a distinct pathway from classical PLC-coupled receptors.\",\n      \"method\": \"Calcium flux assays, inositol phosphate measurements, protein tyrosine phosphorylation assays in murine B cells using mitogenic anti-CD38 antibody NIMR-5\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical assays in single lab, clear mechanistic distinction established\",\n      \"pmids\": [\"7875731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD38 ligation on human NK cells activates a signaling cascade including intracellular Ca2+ elevation, tyrosine phosphorylation of CD3-zeta, FcεRIγ, ZAP-70, and c-Cbl, and induces IFN-γ and GM-CSF secretion and cytolytic function. These CD38-mediated signals were absent in CD16-negative NK cell lines, establishing that CD38 requires CD16 (FcγRIIIA) as a co-signaling partner in NK cells.\",\n      \"method\": \"Calcium flux assays, tyrosine phosphorylation assays, cytokine secretion assays, cytotoxicity assays, genetic complementation of CD16-negative NK lines with CD16 expression\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays, genetic complementation approach, single lab\",\n      \"pmids\": [\"11282979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD38 physically associates with CD16 on the surface of human NK cells, as demonstrated by FRET and cocapping experiments. Functional CD16 is necessary and sufficient for CD38 to control an activation pathway including calcium fluxes, ZAP-70 and MAPK phosphorylation, IFN-γ secretion, and cytotoxic responses, establishing CD38 as a receptor that signals through lineage-specific co-association with professional signaling molecules.\",\n      \"method\": \"FRET, cocapping, calcium flux, tyrosine phosphorylation, IFN-γ secretion, cytotoxicity assays in CD16+ and CD16- NK variants\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — FRET-based physical association plus multiple functional assays, reciprocal genetic approach with CD16+/- NK variants\",\n      \"pmids\": [\"11895784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"During immunological synapse (IS) formation, CD38 redistributes to the T cell–APC contact area in an antigen-dependent manner via Lck-mediated signals. Two distinct pools of CD38 exist—one at the plasma membrane and one in recycling endosomes—and both are recruited to the IS. CD38 overexpression increases antigen-induced intracellular Ca2+ release; siRNA knockdown reduces it. CD38 blockade inhibits IL-2 and IFN-γ production, PKCθ phosphorylation (Thr538), and PKCθ recruitment to the IS.\",\n      \"method\": \"Confocal microscopy, CD38-GFP live imaging, siRNA knockdown, Ca2+ flux assays, cytokine ELISA, PKCθ phosphorylation assays in human T cells and B cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (imaging, genetic KD, Ca2+ flux, signaling assays), two cell types, single lab with rigorous controls\",\n      \"pmids\": [\"18212246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CD38 exists in two opposing membrane orientations on cell surfaces: the canonical type II orientation (catalytic C-terminal domain extracellular) and a type III orientation (catalytic domain facing intracellularly). Site-directed mutagenesis of cationic residues in the N-terminal segment converts the mixed type II/III distribution to exclusively type III. Expression of type III CD38 increases intracellular cADPR concentrations, establishing the type III orientation as critical for intracellular Ca2+ signaling.\",\n      \"method\": \"Orientation-specific antibodies against N-terminal segment, site-directed mutagenesis, intracellular cADPR measurement in transfected HL-60 cells, monocytes, and U937 cells stimulated with IFN-γ\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with orientation-specific antibodies and functional cADPR measurement, orthogonal methods in multiple cell types\",\n      \"pmids\": [\"22969159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD38 activity generates the second messengers NAADP and cADPR. Gene silencing of CD38 did not inhibit NAADP synthesis in intact Jurkat T cells or in thymus/spleen from CD38 knockout mice, but in vitro CD38 efficiently catalyzed both NAADP formation (by base-exchange) and NAADP degradation. This establishes that in vivo CD38 functions as a NAADP-degrading rather than NAADP-synthesizing enzyme, likely preventing desensitizing NAADP levels.\",\n      \"method\": \"CD38 gene silencing (siRNA), CD38 knockout mouse tissues, in vitro enzymatic assays for NAADP formation and degradation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic assay plus genetic KO/KD in intact cells, single lab, clear mechanistic conclusion\",\n      \"pmids\": [\"22020217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD38 produces NAADP in the endolysosomal compartment. Nanobody-induced endocytosis of CD38 via a clathrin-dependent pathway delivers CD38 to lysosomes and elevates cellular NAADP levels. A lysosome-targeted CD38 variant is substantially more active in raising NAADP levels than wild-type CD38, and nicotinic acid supplementation further increases NAADP production, demonstrating that CD38 compartmentalization and substrate access—rather than enzyme activation—regulate NAADP production.\",\n      \"method\": \"Nanobody-directed endocytosis, lysosome-specific CD38 targeting constructs, intracellular NAADP measurement, clathrin inhibitor studies in human cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstitution of lysosomal NAADP production with targeted constructs, multiple orthogonal approaches, substrate access mechanism demonstrated\",\n      \"pmids\": [\"29632067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of CD38 complexed with anti-CD38 nanobodies identified three separate epitopes on the carboxyl (catalytic) domain of CD38. Chromobody (nanobody-fluorescent protein fusions) tools confirmed high CD38 expression on malignant MM cells. An immunotoxin (nanobody fused to bacterial toxin PE38) showed selective cytotoxicity against MM cells at picomolar concentrations.\",\n      \"method\": \"X-ray crystallography of CD38–nanobody complexes, flow cytometry quantification with chromobodies, in vitro cytotoxicity assays with immunotoxin\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures resolve epitopes with functional validation by immunotoxin cytotoxicity, single lab with rigorous structural methods\",\n      \"pmids\": [\"27251573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD38 functions as a receptor that interacts with CD31 (PECAM-1) on the surface of leukocytes, mediating adhesion and signaling. The CD38–CD31 interaction constitutes a ligand–receptor pair governing leukocyte adhesion and transmembrane signaling.\",\n      \"method\": \"Receptor-ligand binding studies, adhesion assays, signaling assays in leukocytes\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct binding interaction identified with functional adhesion readout, replicated across reports cited in review\",\n      \"pmids\": [\"11137554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD38 expression on CLL cells is upregulated by contact with activated CD4+ T cells, is higher in pseudofollicle-containing tissues, and marks proliferating CLL cells associated with CD31+ vascular endothelial cells. This establishes CD38 expression as dynamically regulated by the tumor microenvironment through T cell contact.\",\n      \"method\": \"Flow cytometry, tissue immunohistochemistry, in vitro co-culture of CLL cells with activated CD4+ T cells, comparison of tissue vs. blood CD38 levels\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct co-culture experiment demonstrating T cell-driven CD38 upregulation, supported by tissue analysis, single lab\",\n      \"pmids\": [\"18326821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LPS induces CD38 upregulation at the mRNA level in J774 macrophages via the JAK-STAT pathway and simultaneously causes CD38 shedding from the plasma membrane into the extracellular space via metalloproteinase-9 (MMP-9), as demonstrated by MMP-9 inhibitor blockade of CD38 release.\",\n      \"method\": \"Flow cytometry, RT-PCR, JAK-STAT pathway inhibitors, metalloproteinase-9 inhibitor, ELISA for soluble CD38 in culture supernatant\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway identified with specific inhibitors, single lab, multiple methods\",\n      \"pmids\": [\"23184288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PI3K p110δ regulates CD38 expression on regulatory T cells (Tregs): p110δ-inactivated Tregs fail to develop CD38high cells. CD38high Tregs display superior suppressive activity and upregulate CD73 compared to CD38low Tregs. CD38 marks Tregs with high suppressive capacity downstream of PI3K p110δ signaling.\",\n      \"method\": \"Transcriptome comparison of wild-type vs. p110δ(D910A) Tregs, flow cytometry, Treg suppression assays, CD38+/- heterozygous mouse analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with defined Treg phenotype, multiple cell comparisons, single lab\",\n      \"pmids\": [\"21390257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD38 promotes angiotensin II-induced cardiac hypertrophy by inhibiting SIRT3 expression and activating Ca2+-NFAT signaling. CD38 knockout mice show significantly reduced cardiac hypertrophy and fibrosis after Ang-II infusion compared to wild-type. In H9c2 cardiomyocytes, CD38 RNAi knockdown decreases ANF and BNP gene expression, reduces ROS generation, elevates SIRT3, activates FOXO3 antioxidant pathway, and markedly reduces Ang-II-induced intracellular Ca2+ release and NFATc4 nuclear translocation.\",\n      \"method\": \"CD38 knockout mice with osmotic mini-pump Ang-II infusion, cardiac histology, RNAi knockdown in H9c2 cells, intracellular Ca2+ measurement, Western blotting for SIRT3/FOXO3/NFATc4/ERK/AKT\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO plus in vitro KD with multiple signaling pathway readouts, single lab\",\n      \"pmids\": [\"28296029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"During sepsis resolution, CD38 levels increase to produce Ca2+-signaling messengers (NAADP, ADPR, cADPR) from NAD(P)+. These second messengers induce tristetraprolin (TTP) expression, which then downregulates CD38. Sirt1-dependent TTP deacetylation (activated by increased NAD+ levels) suppresses acute inflammation, decreases Rheb, inhibits mTORC1, and induces autophagolysosomes for bacterial clearance, defining a CD38–TTP feedback loop in inflammation resolution.\",\n      \"method\": \"Sepsis mouse models, CD38 and TTP KO mice, Sirt1 inhibition, mTORC1 signaling assays, autophagolysosome formation assays, second messenger measurements\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO models plus signaling pathway dissection, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31995750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD38 enzymatic activity (NADase) depletes intracellular NAD+ in prostate cancer cells, causing cell-cycle arrest with p21Cip1 upregulation, diminishing glycolytic and mitochondrial metabolism, activating AMPK, and inhibiting fatty acid/lipid synthesis. Expression of an NAD+ hydrolase-deficient CD38 mutant failed to reproduce these metabolic effects, establishing NADase activity as the mechanistic basis.\",\n      \"method\": \"CD38 overexpression and NADase-deficient mutant in prostate cancer cell lines, NAD+ measurement, cell-cycle analysis, metabolic flux assays (Seahorse), AMPK phosphorylation, transcriptome profiling\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — catalytic mutant controls establish enzymatic mechanism, multiple orthogonal metabolic readouts, single rigorous study\",\n      \"pmids\": [\"30076241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD38 overexpression in prostate epithelial cells depletes extracellular (but not intracellular) NAD+ levels, as confirmed by wild-type vs. NAD+ hydrolase-deficient mutant comparisons in cell lines and by NAD+ measurements in urogenital tissues from CD38 knockout vs. wild-type mice.\",\n      \"method\": \"Inducible CD38 overexpression, NADase-deficient CD38 mutant, NAD+ measurements in culture medium and tissues, CD38 KO mouse urogenital tissue analysis\",\n      \"journal\": \"Cancer & metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — catalytic mutant plus KO mouse model with direct NAD+ measurements, single lab with rigorous controls\",\n      \"pmids\": [\"30258629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pro-inflammatory M1-like macrophages accumulate in visceral adipose tissue and liver during aging and express high levels of CD38 with enhanced CD38-dependent NADase activity, thereby reducing tissue NAD+ levels. Senescent cell-derived SASP cytokines induce macrophages to proliferate and upregulate CD38, establishing a causal chain: senescence → SASP → macrophage CD38 induction → NAD+ decline.\",\n      \"method\": \"Flow cytometry of tissue macrophage subsets, CD38 NADase activity assays, senescent cell depletion, SASP cytokine treatment of macrophages, tissue NAD+ measurement in aged mice\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct CD38-dependent NADase activity measurements in isolated macrophages, SASP induction experiments, senescent cell depletion rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"33199924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In human macrophages and monocytes, CD38 expression is robustly induced by LPS ± IFN-γ but not by IL-4. Pharmacologic and/or genetic CD38 loss-of-function significantly reduced secretion of inflammatory cytokines IL-6 and IL-12p40 and glycolytic activity in primary human macrophages.\",\n      \"method\": \"LPS/IFN-γ/IL-4 stimulation of human primary macrophages, siRNA knockdown, pharmacological inhibition, ELISA for cytokines, glycolysis assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological KD with functional cytokine and metabolic readouts, single lab, multiple methods\",\n      \"pmids\": [\"30042766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Daratumumab (anti-CD38 antibody) induces rapid CD38 protein internalization and degradation on NK cells, leaving an activated CD38-negative NK cell population. CD38+ NK cell targeting by daratumumab promotes monocyte activation, increasing T-cell costimulatory molecules (CD86/CD80) and enhancing anti-MM phagocytosis.\",\n      \"method\": \"Flow cytometry of NK cell CD38 expression after daratumumab treatment, monocyte activation assays, co-culture cytotoxicity/phagocytosis assays ex vivo and in vivo (mouse xenograft)\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein internalization/degradation measured by flow cytometry with functional monocyte activation readout, single lab\",\n      \"pmids\": [\"32296125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Daratumumab treatment causes CD38 internalization on MM cell surfaces via dynamin-dependent endocytosis and impairs MM cell adhesion; this adhesion impairment can be rescued by the endocytosis inhibitor Dynasore. CD38 internalization-mediated loss of adhesion increases MM cell sensitivity to bortezomib.\",\n      \"method\": \"Flow cytometry of surface CD38 after daratumumab, Dynasore endocytosis inhibitor rescue of adhesion, in vitro and in vivo bortezomib combination studies\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endocytosis inhibitor rescue experiment mechanistically links internalization to adhesion impairment, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"30288349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD38 modulates B-cell receptor (BCR) signaling in CLL: interference with CD38 downregulates Syk, BTK, PLCγ2, ERK1/2, and AKT phosphorylation. Daratumumab additionally induces direct apoptosis of primary CLL cells partially dependent on FcγR cross-linking, beyond its immune-effector mechanisms.\",\n      \"method\": \"Immunoblotting of BCR signaling intermediates after CD38 targeting/blockade, apoptosis assays, FcγR blocking experiments, in vivo CLL xenograft model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Western blotting of signaling cascade downstream of CD38, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"30940652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD38 elevation in alveolar epithelial cells (AECs) downregulates intracellular NAD+, impairing NAD-dependent cellular activities and promoting cellular aging phenotypes and lung fibrosis. Genetic and pharmacological inactivation of CD38 improved NAD-dependent events and ameliorated bleomycin-induced lung fibrosis in mice.\",\n      \"method\": \"scRNA-seq, Western blotting, flow cytometry, CD38 KO mice, pharmacological CD38 inhibition, bleomycin fibrosis model, NAD+ measurement\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with NAD+ measurement and fibrosis readout, single lab\",\n      \"pmids\": [\"35687485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD38 expression in the ovary increases with reproductive age, and CD38 knockout mice exhibit larger primordial follicle pools, elevated ovarian NAD+ levels, and increased fecundity. The larger ovarian reserve results from a prolonged window of follicle formation during early development, establishing that CD38-dependent NAD+ consumption accelerates the depletion of ovarian reserve.\",\n      \"method\": \"CD38 KO mouse reproductive phenotyping, ovarian NAD+ measurement, primordial follicle counting, fecundity assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with direct NAD+ measurement and follicle reserve quantification, single lab, clean loss-of-function\",\n      \"pmids\": [\"37822499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pharmacological inhibition or genetic knockout of CD38 in chondrocytes increases the intracellular NAD+:NADH ratio and reduces catabolic responses to IL-1β. In vivo, CD38-deficient mice show significantly reduced cartilage degradation, synovial inflammation, osteophyte formation, subchondral bone sclerosis, and pain-like behavior after joint injury.\",\n      \"method\": \"CD38 overexpression and pharmacological inhibition in chondrocytes, NAD+:NADH ratio measurement, catabolic gene expression, CD38 KO mice with DMM surgery, cartilage histology, pain behavior assays\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with direct NAD+:NADH measurement, in vivo KO model with multiple disease readouts, single lab\",\n      \"pmids\": [\"36103412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"High CD38 expression increases cellular ROS levels and induces oxidative degradation of dihydrofolate reductase (DHFR) via sulfonation of Cys7, leading to DHFR degradation through autophagy and non-canonical proteasome pathways. This DHFR loss increases cellular susceptibility to ferroptosis. Mutation of DHFR Cys7 to alanine abolishes ROS-induced degradation, and NMN supplementation (to restore NAD+) prevents DHFR degradation and ferroptosis susceptibility.\",\n      \"method\": \"CD38 overexpression, ROS measurement, site-directed mutagenesis of DHFR Cys7, autophagy/proteasome pathway inhibitors, ferroptosis assays, aged vs. young bone-marrow-derived macrophage comparisons, NMN supplementation rescue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis identifies specific residue, multiple pathway inhibitors, rescue by NAD+ precursor, single lab\",\n      \"pmids\": [\"36351893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TNB-738, a biparatopic anti-CD38 antibody binding two non-competing epitopes simultaneously, potently inhibits CD38 ecto-enzyme activity, boosting intracellular NAD+ levels and sirtuin (SIRT) activities without depleting CD38-expressing cells (due to silenced IgG4 Fc).\",\n      \"method\": \"Fluorescence spectroscopy enzymatic activity assays, intracellular NAD+ measurement, sirtuin activity assays, ADCC/CDC assays confirming lack of cell depletion, SPR binding studies\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct enzymatic inhibition assay with functional NAD+ and SIRT activity readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35867844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HexaBody-CD38 binds a unique epitope on CD38 (identified by co-crystallization) and strongly inhibits CD38 cyclase activity. The E430G Fc mutation facilitates antibody hexamerization upon cell-surface binding, increasing C1q recruitment and potentiating complement-dependent cytotoxicity (CDC) compared to daratumumab.\",\n      \"method\": \"Co-crystallization of HexaBody-CD38 with CD38, fluorescence spectroscopy for cyclase inhibition, CDC/ADCC/ADCP/apoptosis flow cytometry assays, patient-derived xenograft mouse models\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — crystal structure defines epitope, direct enzymatic inhibition assay, multiple effector mechanism assays, in vivo xenograft validation\",\n      \"pmids\": [\"37379657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In vitro activation of CLL cells through CD38 drives proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2, establishing CD38 as a functional signal transducer promoting CLL cell survival and migration.\",\n      \"method\": \"CD38 ligation assays in CLL cells, Western blotting of ZAP-70 and ERK1/2 phosphorylation, proliferation and chemotaxis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct signaling assays linking CD38 ligation to defined kinase pathway and functional readouts, replicated across multiple CLL studies\",\n      \"pmids\": [\"21765022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human monocytes rapidly degrade extracellular NAD+ to nicotinamide and ADP-ribose via surface CD38 (NAD+-glycohydrolase activity). Anti-CD38 mAb ligation induces CD38 internalization and shedding. Monocyte-to-macrophage differentiation downregulates surface CD38 expression at the transcriptional level, correlating with reduced NADase activity.\",\n      \"method\": \"NAD+ degradation product analysis (HPLC), flow cytometry, RT-PCR, anti-CD38 mAb internalization assays, monocyte-to-macrophage differentiation experiments\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct NADase activity measurement linked to CD38 expression level, internalization demonstrated, transcriptional regulation identified, single lab\",\n      \"pmids\": [\"11683883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD38 knockout mice exhibit deficits in spatial memory (Morris water maze), contextual fear conditioning, and object recognition memory. However, hippocampal long-term potentiation and long-term depression are intact in CD38−/− mice, indicating CD38 is required for hippocampus-dependent learning and memory through mechanisms independent of synaptic plasticity.\",\n      \"method\": \"Morris water maze, contextual fear conditioning, object recognition tests in CD38−/− mice, electrophysiological LTP/LTD recordings in hippocampal slices\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with multiple behavioral paradigms and electrophysiology controls, single lab, specific mechanistic dissociation\",\n      \"pmids\": [\"26856703\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD38 is a multifunctional type II transmembrane glycoprotein that acts as a bifunctional ectoenzyme catalyzing synthesis and hydrolysis of cyclic ADP-ribose (cADPR) and NAADP from NAD(P)+, primarily depleting cellular NAD+ pools; it exists in two opposing membrane orientations (type II extracellular and type III intracellular catalytic domain), with the type III orientation driving intracellular cADPR accumulation and Ca2+ signaling; NAADP is produced specifically in the endolysosomal compartment upon CD38 internalization; as a receptor, CD38 signals through lineage-specific co-association with professional signaling molecules (e.g., CD16 in NK cells) to activate ZAP-70, MAPK, and Ca2+ cascades, and is recruited to the immunological synapse via Lck-dependent mechanisms to modulate PKCθ and cytokine production; CD38-mediated NAD+ depletion regulates macrophage inflammatory cytokine production, T cell metabolism, cardiac hypertrophy via SIRT3/Ca2+-NFAT signaling, and tissue aging across multiple organ systems.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD38 is a multifunctional type II transmembrane glycoprotein that acts both as a bifunctional ectoenzyme and as a lineage-specific signaling receptor, coupling NAD(P)+ metabolism to calcium signaling, immune activation, and tissue NAD+ homeostasis [#0, #4, #18]. Enzymatically, CD38 catalyzes the synthesis and hydrolysis of the Ca2+-mobilizing second messenger cyclic ADP-ribose, acting independently of inositol trisphosphate, and also degrades extracellular NAD+ to nicotinamide and ADP-ribose via its NAD+-glycohydrolase activity [#0, #2, #30]. A topological feature underlies its second-messenger function: CD38 occupies two opposing membrane orientations, and the type III orientation (catalytic domain facing the cytosol) drives intracellular cADPR accumulation and Ca2+ signaling [#6]. For NAADP, in vivo CD38 functions chiefly as a degrading rather than synthesizing enzyme, and NAADP production is controlled by compartmentalization: clathrin-dependent internalization delivers CD38 to the endolysosome where substrate access raises NAADP levels [#7, #8]. As a receptor, CD38 signals through co-association with professional signaling molecules—physically associating with CD16 (Fc\\u03b3RIIIA) in NK cells to drive ZAP-70/MAPK phosphorylation, Ca2+ flux, and cytokine secretion, and binding CD31 (PECAM-1) to mediate leukocyte adhesion [#4, #10]. CD38 is recruited to the immunological synapse in an antigen- and Lck-dependent manner from both plasma-membrane and recycling-endosome pools, modulating PKC\\u03b8 activation and IL-2/IFN-\\u03b3 production [#5]. Across multiple tissues, CD38-mediated NAD+ depletion is a central driver of pathology: its NADase activity arrests prostate cancer cell metabolism, inflammatory macrophages upregulate CD38 to lower tissue NAD+ during aging, and CD38 loss is protective in cardiac hypertrophy, lung fibrosis, osteoarthritis, and ovarian reserve depletion via NAD+- and SIRT-dependent mechanisms [#16, #18, #14, #23, #25, #24]. Catalytic-mutant controls establish that NADase activity, not receptor function, underlies these metabolic effects [#16, #17]. Structurally characterized epitopes on the catalytic domain underpin therapeutic anti-CD38 antibodies that act by cell depletion, cyclase/ecto-enzyme inhibition that boosts NAD+ and sirtuin activity, or dynamin-dependent CD38 internalization [#9, #27, #28, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that CD38 receptor ligation transduces signals through a non-canonical pathway, distinguishing it from classical PLC-coupled receptors.\",\n      \"evidence\": \"Calcium flux, inositol phosphate, and tyrosine phosphorylation assays in murine B cells with anti-CD38 antibody\",\n      \"pmids\": [\"7875731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the kinases or co-receptors mediating the tyrosine phosphorylation\", \"No direct link to a downstream functional output\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined CD38 as a bifunctional ectoenzyme producing and degrading the Ca2+-mobilizing messenger cADPR, reframing it from a pure surface marker to a metabolic enzyme.\",\n      \"evidence\": \"Biochemical ectoenzyme assays and antibody-ligation/internalization studies in hematopoietic cells\",\n      \"pmids\": [\"8903511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how an ectoenzyme generates an intracellular messenger (topological paradox)\", \"Receptor versus enzyme contributions not separated\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Proposed resolutions to the topological paradox—cADPR transport across the membrane and NAD+-induced CD38 internalization—addressing how surface enzyme activity reaches intracellular stores.\",\n      \"evidence\": \"Biochemical fractionation and NAD+-induced internalization experiments in lymphoid B cells\",\n      \"pmids\": [\"9438379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Two mechanisms with partial support; relative contributions unresolved\", \"Transport route for extracellular cADPR not molecularly defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the receptor partners and downstream signaling required for CD38 to drive NK and leukocyte function, showing CD38 needs CD16 as a co-signaling partner and binds CD31 for adhesion.\",\n      \"evidence\": \"Genetic complementation of CD16-negative NK lines, signaling/cytokine assays, and CD38\\u2013CD31 binding/adhesion assays\",\n      \"pmids\": [\"11282979\", \"11137554\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular nature of the CD38\\u2013CD16 physical interaction not yet shown\", \"CD31 binding affinity and stoichiometry not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Linked CD38 surface NADase activity to expression level and internalization in monocytes, connecting enzyme function to cell differentiation state.\",\n      \"evidence\": \"HPLC NAD+ degradation product analysis, flow cytometry, RT-PCR, and differentiation experiments in human monocytes\",\n      \"pmids\": [\"11683883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of NAD+ depletion for monocyte biology not addressed\", \"Mechanism of transcriptional downregulation during differentiation unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated direct physical association of CD38 with CD16 and that CD16 is necessary and sufficient for CD38-driven NK activation, establishing the co-association model of CD38 receptor signaling.\",\n      \"evidence\": \"FRET and cocapping with functional Ca2+/phosphorylation/cytokine/cytotoxicity readouts in CD16+/- NK variants\",\n      \"pmids\": [\"11895784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other lineages use distinct co-receptors not tested here\", \"Enzyme activity contribution to NK signaling not separated from receptor function\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed CD38 is recruited to the immunological synapse via Lck-dependent signals from membrane and recycling-endosome pools to amplify Ca2+ and modulate PKC\\u03b8 and cytokine output in T cells.\",\n      \"evidence\": \"Confocal/live imaging of CD38-GFP, siRNA knockdown, Ca2+ flux, ELISA, and PKC\\u03b8 phosphorylation in human T and B cells\",\n      \"pmids\": [\"18212246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor that triggers CD38 redistribution not identified\", \"Whether enzymatic activity is required for synapse function unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Refined CD38's NAADP role, showing it acts in vivo as a NAADP-degrading rather than synthesizing enzyme, implying it limits desensitizing NAADP accumulation.\",\n      \"evidence\": \"siRNA silencing and CD38 KO mouse tissues versus in vitro enzymatic NAADP formation/degradation assays\",\n      \"pmids\": [\"22020217\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the in vivo NAADP synthase left open\", \"Reconciliation with later compartmentalized NAADP production needed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected CD38 expression to immune-regulatory and tumor signaling, marking highly suppressive Tregs downstream of PI3K p110\\u03b4 and driving CLL proliferation/chemotaxis via ZAP-70/ERK.\",\n      \"evidence\": \"p110\\u03b4(D910A) Treg transcriptomics/suppression assays and CD38-ligation signaling/proliferation assays in CLL cells\",\n      \"pmids\": [\"21390257\", \"21765022\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CD38 enzymatic vs receptor activity drives these phenotypes unclear\", \"Direct receptor partners in CLL not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved the topological paradox at the molecular level by demonstrating two opposing membrane orientations, with the type III (cytosol-facing catalytic) orientation enabling intracellular cADPR/Ca2+ signaling.\",\n      \"evidence\": \"Orientation-specific antibodies, site-directed mutagenesis of N-terminal cationic residues, and intracellular cADPR measurement in multiple cell types\",\n      \"pmids\": [\"22969159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism determining orientation choice during biogenesis unknown\", \"Physiological proportion of type III in primary cells not quantified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined inflammatory regulation of CD38, with LPS inducing CD38 transcription via JAK-STAT and MMP-9 shedding releasing soluble CD38.\",\n      \"evidence\": \"RT-PCR, JAK-STAT and MMP-9 inhibitor studies, and ELISA for soluble CD38 in J774 macrophages\",\n      \"pmids\": [\"23184288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Function of shed soluble CD38 not established\", \"STAT transcription factor identity not pinned down\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided structural epitope maps of the CD38 catalytic domain and proof-of-concept that targeting it selectively kills malignant cells.\",\n      \"evidence\": \"X-ray crystallography of CD38\\u2013nanobody complexes and immunotoxin cytotoxicity against multiple myeloma cells\",\n      \"pmids\": [\"27251573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures did not address membrane orientation or full-length context\", \"Enzymatic effect of epitope binding not measured\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established that CD38 NADase activity—not receptor signaling—drives metabolic reprogramming, depleting intracellular and extracellular NAD+ to arrest cell cycle and metabolism, using catalytic-dead mutant controls.\",\n      \"evidence\": \"CD38 overexpression with NADase-deficient mutant, NAD+ measurement, Seahorse flux, cell-cycle and AMPK assays, plus KO mouse tissue NAD+ in prostate models\",\n      \"pmids\": [\"30076241\", \"30258629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether type II vs type III orientation governs intracellular NAD+ depletion not addressed\", \"Source NAD+ pool (cytosolic vs extracellular import) for intracellular effects not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed CD38 NAADP production is governed by subcellular localization, with clathrin/lysosome targeting—not enzyme activation—setting NAADP output.\",\n      \"evidence\": \"Nanobody-directed endocytosis, lysosome-targeted CD38 constructs, clathrin inhibition, and intracellular NAADP measurement in human cells\",\n      \"pmids\": [\"29632067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger for endogenous CD38 lysosomal trafficking not identified\", \"Link between lysosomal NAADP and specific Ca2+ channels not shown here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined CD38 as an inducible amplifier of macrophage inflammation, required for IL-6/IL-12p40 secretion and glycolysis under classical activation.\",\n      \"evidence\": \"LPS/IFN-\\u03b3/IL-4 stimulation with siRNA and pharmacological CD38 inhibition and cytokine/glycolysis assays in primary human macrophages\",\n      \"pmids\": [\"30042766\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether enzymatic NAD+ depletion mediates the cytokine effect not separated\", \"Downstream metabolic node linking CD38 to glycolysis undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Clarified mechanisms of anti-CD38 therapeutics, showing daratumumab induces dynamin/clathrin-dependent CD38 internalization and degradation that reshapes NK/monocyte function and impairs MM adhesion to sensitize to bortezomib.\",\n      \"evidence\": \"Flow cytometry of surface CD38 after daratumumab, Dynasore rescue of adhesion, monocyte activation/phagocytosis and bortezomib combination assays in vitro and in vivo\",\n      \"pmids\": [\"32296125\", \"30288349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Adapter machinery driving antibody-induced internalization not fully defined\", \"Relative contribution of internalization vs effector killing in patients unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Implicated CD38 NAD+ depletion in cardiac disease, linking it to SIRT3 suppression and Ca2+-NFAT signaling in angiotensin II-induced hypertrophy.\",\n      \"evidence\": \"CD38 KO mice with Ang-II infusion, cardiac histology, and RNAi knockdown with signaling readouts in H9c2 cardiomyocytes\",\n      \"pmids\": [\"28296029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration that NADase activity (not receptor) drives the SIRT3 axis not shown\", \"Cell type responsible (cardiomyocyte vs infiltrating cells) in vivo not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended CD38 signaling control to B-cell receptor pathways in CLL and showed daratumumab can directly trigger Fc\\u03b3R-dependent apoptosis.\",\n      \"evidence\": \"Immunoblotting of Syk/BTK/PLC\\u03b32/ERK/AKT after CD38 targeting, apoptosis and Fc\\u03b3R-blocking assays, and CLL xenografts\",\n      \"pmids\": [\"30940652\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic coupling of CD38 to the BCR module not structurally defined\", \"Whether ectoenzyme activity participates not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined feedback and aging circuits of CD38 NADase, with a CD38\\u2013TTP\\u2013Sirt1 loop resolving sepsis inflammation and senescence-driven macrophage CD38 induction lowering tissue NAD+ during aging.\",\n      \"evidence\": \"Sepsis models with CD38/TTP KO and Sirt1 inhibition; tissue macrophage NADase activity, SASP induction, and senescent cell depletion in aged mice\",\n      \"pmids\": [\"31995750\", \"33199924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptors/transcription factors linking SASP to CD38 induction incompletely mapped\", \"Whether other NAD-consuming enzymes contribute to tissue decline not excluded\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked CD38-driven NAD+ loss to oxidative damage and ferroptosis, with high CD38 raising ROS and causing Cys7-sulfonation-dependent DHFR degradation rescuable by NAD+ precursor.\",\n      \"evidence\": \"CD38 overexpression, ROS measurement, DHFR Cys7 mutagenesis, autophagy/proteasome inhibitors, ferroptosis assays, and NMN rescue\",\n      \"pmids\": [\"36351893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic-mutant control for CD38 NADase in this pathway not described\", \"Generality across cell types beyond macrophages unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Generalized CD38 NAD+ depletion as a driver of tissue fibrosis and aging, with CD38 elevation in alveolar epithelial cells promoting senescence and lung fibrosis.\",\n      \"evidence\": \"scRNA-seq, CD38 KO and pharmacological inhibition, NAD+ measurement, and bleomycin fibrosis model in mice\",\n      \"pmids\": [\"35687485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic-mutant proof in epithelium not provided\", \"Trigger of CD38 elevation in AECs not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated therapeutic enzyme inhibition without cell killing as a distinct anti-CD38 strategy, with a biparatopic Fc-silenced antibody inhibiting ecto-enzyme activity and boosting NAD+ and sirtuin activity.\",\n      \"evidence\": \"Fluorescence enzymatic assays, intracellular NAD+ and sirtuin activity measurement, SPR binding, and ADCC/CDC assays for TNB-738\",\n      \"pmids\": [\"35867844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo NAD+ restoration efficacy not detailed here\", \"Durability of enzyme inhibition not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Combined structural epitope definition with dual therapeutic mechanism, showing a HexaBody antibody inhibits CD38 cyclase activity while Fc hexamerization potentiates complement-dependent killing.\",\n      \"evidence\": \"Co-crystallization, cyclase inhibition spectroscopy, CDC/ADCC/ADCP/apoptosis assays, and patient-derived xenografts\",\n      \"pmids\": [\"37379657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cyclase inhibition contributes clinically beyond killing not resolved\", \"Epitope effect on type III orientation not examined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended CD38 NAD+ consumption to reproductive aging and joint disease, with CD38 loss enlarging ovarian reserve and protecting cartilage after injury via raised NAD+.\",\n      \"evidence\": \"CD38 KO mouse ovarian phenotyping/NAD+ measurement and chondrocyte gain/loss-of-function with NAD+:NADH measurement plus DMM joint injury model\",\n      \"pmids\": [\"37822499\", \"36103412\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-autonomous vs systemic NAD+ effects not fully separated\", \"Whether receptor signaling contributes alongside NADase not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a neurological requirement for CD38 in learning and memory that is independent of classical synaptic plasticity.\",\n      \"evidence\": \"Behavioral testing (water maze, fear conditioning, object recognition) and hippocampal LTP/LTD electrophysiology in CD38 KO mice\",\n      \"pmids\": [\"26856703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediator (cADPR/Ca2+ vs oxytocin-related signaling) not identified here\", \"Brain cell type responsible not localized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the determinants of CD38 membrane orientation and subcellular trafficking are physiologically regulated to dictate when CD38 depletes NAD+ versus generates compartmentalized Ca2+ messengers remains unresolved.\",\n      \"evidence\": \"No timeline discovery defines the in vivo signals controlling type II/III orientation choice or endolysosomal targeting\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Biogenic mechanism setting orientation unknown\", \"Endogenous trigger for lysosomal trafficking undefined\", \"Integration of enzyme vs receptor roles in a single cell not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 7, 8, 16, 30]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 16, 30]},\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [0, 28]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 4, 5]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 30]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [5, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 4, 5, 18, 19]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 17, 18, 23, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 29]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [18, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD16\", \"CD31\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}